Morningstar

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules ...
Nasdaq

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...
KXAN

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...
Healio

FDA approves Ingrezza sprinkle capsules for tardive dyskinesia, Huntington’s chorea

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...
Seeking Alpha

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences (NBIX), Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 ...

Scientists may have discovered first gene therapy for incurable brain disease

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...
Hosted on MSN

Is Huntington’s Disease Genetic? Here’s Everything You Should Know

People with Huntington’s disease often lose control over their voluntary movements, which can affect daily functioning more severely than the involuntary jerks caused by chorea. Difficulties with ...

First Juvenile Huntington’s Disease brain donated to NIMHANS for research

Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.
Nasdaq

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...